RNAi Therapeutics Market Size Share Trends Growth Demand and Competitive Analysis Insights 2022-2029 | DataM Intelligence

November 08 19:22 2022
RNAi Therapeutics Market Size Share Trends Growth Demand and Competitive Analysis Insights 2022-2029 | DataM Intelligence
DataM Intelligence
RNAi Therapeutics Market is expected to grow at a CAGR of 17.4% during the forecast period 2022-2029.

Market Overview:

RNAi Therapeutics Market is expected to grow at a CAGR of 17.4% during the forecast period 2022-2029. As per Priority Exploration, the worldwide red biotechnology market size is anticipated to hit around US$ 510 billion by 2027 from an estimated at US$ 322 billion out of 2022. The North America region has the highest market share in the RNAi Therapeutics Market, and it is further continuing its dominance during the forecast period.

Our research report gives wide perceptions of the latest trends and development prospects of the market analysis, detailed segmentation analysis, volume, size, share, growth drives, and opportunities in the market. In-depth regional and country-level illustration of the competitive landscape depends on several phases and status of clinical trials over the prominent economies of the globe, and also the report contains a number of major companies profiled in the relevant market.

To Download free sample @ Click Here

Market Drivers:

High venture and severe guidelines are probably going to hamper the market development

As of late, there has been a decrease in FDA drug endorsement rates. Getting FDA endorsement for another medication has become incredibly testing. It supported not exactly a portion of the quantity of new medications in 2016 (19 up to this point) when contrasted with 2015 (45 aggregate) and 2014 (41 aggregate). Thus, notwithstanding the enormous speculations, there has been a decrease in imaginative medications made. FDA makes sense of assembling principles and other consenting issues as the significant purposes behind this declining pattern. This can obstruct the development of the RNAi therapeutics, particularly since the miRNAs and siRNAs fall into the somewhat new field of hereditary medication, wherein they might require more increased clinical preliminaries. The exceptionally broad clinical preliminaries successfully bring about low endorsement paces of medications. This would imply that the severe rules will be a significant restriction on the development of the market.

Market Segmentation:

By Type

Small Interfering RNAs (siRNA)

ONPATTRO

GIVLAARI

OXLUMO

By Application

Oncology

Cardiovascular

Respiratory Disorders

Renal Diseases

By Route of Administration

Pulmonary Delivery

Intravenous Injections

Intradermal Injections

Intraperitoneal Injections

By End-User                   

Hospitals

Research and Academic Laboratories

Diagnostic Laboratories

Major Companies Covered:

Alnylam Pharmaceuticals, Inc, Dicerna Pharmaceuticals, Silence Therapeutics, Arrowhead Pharmaceuticals, Inc, Sanofi, GlaxoSmithKline Plc, Arbutus Biopharma Corporation, Benitec Biopharma, Thermo Fisher Scientific Inc and Sirnaomics, Inc. 

Trending Topics:

Metachromatic leukodystrophy Treatment Market

Pheochromocytoma Market

 

Spinal Cord Tumor Market

Media Contact
Company Name: DataM Intelligence
Contact Person: Sai
Email: Send Email
Phone: +1 877 441 4866
Country: United States
Website: https://www.datamintelligence.com/research-report/rnai-therapeutics-market